Making a Meaningful Difference in the Lives of Patients with Rare Diseases
Ascendis Pharma is building an integrated, rare disease-focused biopharmaceutical company to advance its pipeline of long-acting prodrug therapies. We employ our proprietary TransCon technology platform to generate therapeutics with best-in-class profiles that address significant unmet medical needs. We have a diversified and balanced high-value product pipeline, including internal programs and partnerships with market leaders.
Late-stage TransCon Growth Hormone
We have initiated a Phase 3 study—the heiGHt Trial—for our once-weekly TransCon Growth Hormone product candidate. TransCon Growth Hormone is the only long-acting growth hormone in development that has been shown to provide sustained-release of native growth hormone into the bloodstream at the same peak and total exposure levels as approved daily growth hormone. Read More
Proprietary Technology Platform
Our TransCon technology creates novel, sustained-release prodrugs of proteins, peptides and small molecules, suitable for either local or systemic treatment. By solving the fundamental limitations of previous approaches applied to extend duration of a drug’s action in the body, Ascendis Pharma believes its TransCon technology can enhance the benefit of a given therapeutic. Read More